The Preliminary Efficacy And Safety Data Of Kn046 In Patients Failed On Prior Immune Checkpoint Inhibitors Therapy.

Hongyun Zhao,Yuxiang Ma,Yang Zhang,Shaodong Hong,Yunpeng Yang,Wenfeng Fang,June Xu,Hardy Van,Paul Kong,Fei Yang, Jingying Li,Yao Lu,Li Zhang

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 13|浏览25

暂无评分

摘要

3020Background: KN046 is a bispecific antibody that blocks PD-L1 and CTLA-4 by interaction with PD1 and CD80/CD86. KN046-CHN-001 (NCT03529526) is a, dose escalation and expansion phase Ia/Ib clinic...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要